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Abstract
Background: Fibrolamellar hepatocellular carcinoma (FLC) is a rare malignancy occurring in young patients without
cirrhosis. Objectives of our study were to analyze contrast material uptake in hepatobiliary phase imaging (HBP) in
gadoxetic acid-enhanced liver MRI in patients with FLC and to characterize imaging features in sequence techniques
other than HBP.
Methods: In this retrospective study on histology-proven FLC, contrast material uptake in HBP was quantitatively
assessed by calculating the corrected FLC enhancement index (CEI) using mean signal intensities of FLC and
lumbar muscle on pre-contrast imaging and HBP, respectively. Moreover, enhancement patterns in dynamic
contrast-enhanced MRI and relative signal intensities compared with background liver parenchyma were determined by
two radiologists in consensus for HBP, diffusion-weighted imaging using high b-values (DWI), and T2 and T1 weighted
pre-contrast imaging.
Results: In 6 of 13 patients with FLC gadoxetic acid-enhanced liver MRI was available. The CEI suggested presence of HBP
contrast material uptake in all FLCs. A mean CEI of 1.35 indicated FLC signal increase of 35% in HBP compared with pre-
contrast imaging. All FLCs were hypointense in HBP compared with background liver parenchyma. Three of 6 FLCs had
arterial hyperenhancement and venous wash-out. In DWI and T2 weighted imaging, 5 of 6 FLCs were hyperintense. In T1
weighted imaging, 5 of 6 FLCs were hypointense.
Conclusion: Hepatobiliary uptake of gadoxetic acid was quantitatively measurable in all FLCs investigated in our study.
The observation of hypointensity of FLCs in HBP compared with background liver parenchyma emphasizes the role of
gadoxetic acid-enhanced liver MRI for non-invasive diagnosis of FLC and its importance in the diagnostic work-up of
indeterminate liver lesions.
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Background
Fibrolamellar hepatocellular carcinoma (FLC) is a very
rare form of primary hepatic cancer accounting for ap-
proximately 5% of all hepatocellular carcinomas (HCCs)
[1]. FLCs are composed of well-differentiated neoplastic
hepatocytes surrounded by fibrous bands often arranged
in lamellar distribution [2]. The molecular basis for the
difference between conventional HCC and FLC has
recently been elucidated: a translocation resulting in a
fusion transcript of the DNAJB1- and PRKACA-genes
can be found in all patients with FLC, but not in other
forms of liver cancer [3, 4]. Aside from these specific
histologic and molecular properties, FLC has decisive
clinical features that differ from conventional HCC: FLC
develops preferably de novo in the non-cirrhotic liver of
young patients without history of chronic liver disease.
From a radiologists’ point of view, it is of utmost im-
portance to distinguish FLC from focal nodular hyper-
plasia (FNH). FNH is a hepatic tumor that is observed in
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young patients without chronic liver disease as well, but
is always benign, has no potential for malignant trans-
formation and requires no specific therapy. Radiologic
discrimination between FLC and FNH can be challenging
in magnetic resonance imaging (MRI) because FLC and
FNH share important imaging features in pre-contrast
and post-contrast scans using conventional extracellular
gadolinium-based contrast agents [5–7]. Overlapping
imaging features include the presence of a central scar
and hypervascularity in arterial phase post-contrast scans.
Considering MRI after injection of gadoxetic acid as a liver-
specific contrast agent eliminated significantly via the biliary
system (Primovist or Eovist; Bayer Vital, Leverkusen,
Germany), it is well known that FNH typically shows
enhancement during hepatobiliary phase imaging due
to hepatocellular uptake of contrast material [8]. To our
knowledge, there are incomplete data investigating the be-
havior of FLC on MRI using liver-specific contrast material.
Primary objective of this study was to investigate pres-
ence of enhancement of FLC in post-contrast hepatobiliary
phase MRI. Secondary objectives of this study were to
describe general imaging features of FLC including morph-
ology and distribution, relative signal intensities in con-
ventional sequence techniques other than post-contrast
hepatobiliary phase MRI and presence of accompanying
findings.
Methods
Study design and study population
This analysis was a retrospective single-center exploratory
study on patients that have been identified by chart review
of prospectively generated institutional research databases.
Approval by the local institutional review board was avail-
able. Requirements for inclusion were (1) histology-proven
FLC, (2) age ≥ 18 years, and (3) availability of gadoxetic
acid-enhanced MRI. If patients had undergone local min-
imally invasive interventions (i.e. transarterial chemoembo-
lisation [TACE]) prior to gadoxetic acid-enhanced MRI,
only viable FLC components were considered. Clinical data
were reported via an electronic medical record by the at-
tending oncologists and medical staff. Information included
time to FLC diagnosis, primary differential diagnoses
on prior imaging studies other than gadoxetic acid-
enhanced MRI, and clinical evidence of chronic liver
disease. Time to FLC diagnosis was defined as the time
period between initial evidence of a hepatic mass and
histological diagnosis of malignancy.
Image analysis
The following sequence techniques covering the liver
parenchyma were intended to be included: T2-weighted
images without fat saturation (T2wi), pre-contrast T1-
weighted images with and without fat-saturation (T1wi),
high b-value diffusion weighted images (DWI), and hepatic
arterial phase (HAP), portal venous phase (PVP), and hepa-
tobiliary phase (HBP) post-contrast T1-weighted images
with fat saturation.
A consensus review of all images was performed by two
radiologists. For each imaging sequence, the predominant
signal intensities and their homogeneity were visually
graded as hyperintense, hypointense, or isointense com-
pared with background liver parenchyma. For quantitative
assessment of FLC enhancement, the corrected enhance-
ment index (CEI) was determined for each FLC according
to an approach published by Watanabe et al. for hepato-
biliary phase liver parenchyma enhancement using the
following formula [9]:
CEI ¼ SI liver HBP=SI muscle HBPð Þ= SI liver PRE=SI muscle PREð Þ;
where “SI liver HBP” is the FLC signal intensity in HBP,
“SI muscle HBP” is the lumbar muscle signal intensity in
HBP, “SI liver PRE” is the FLC signal intensity in pre-
contrast T1wi with fat saturation, and “SI muscle PRE”
is the lumbar muscle signal intensity in pre-contrast
T1wi with fat saturation. Signal intensities were
assessed using region of interest (ROI) analyses. El-
lipsoid ROIs were drawn on representative areas of
viable FLC and lumbar muscle on the same slice.
Liver and muscle ROIs, respectively, were equivalent
concerning size and location for both pre-contrast
imaging and HBP. Each measurement was performed
three times, and the mean signal intensity was used
for CEI calculation.
Predominant enhancement patterns from HAP to PV
compared with background liver parenchyma were
assigned to either APHE/WO pattern (arterial phase
hyperenhancement followed by portal venous hypoen-
hancement), non-APHE/WO pattern.
Accompanying findings including presence of intrale-
sional necrosis or hemorrhage, bile duct dilatation, bile duct
tumor thrombosis, and portal vein tumor thrombosis were
analyzed. Presence of intralesional necrosis or hemorrhage
was only considered evaluable in patients that had no
history of TACE.
Results
Patients
Of a total of 13 FLC patients, 6 patients were identified
meeting our inclusion criteria. Clinical information on these
6 study patients is summarized in Table 1. Median age at
FLC diagnosis was 37 years (range 18–65), and 3 patients
were female. FLC diagnosis was delayed in 2 patients with
time to FLC diagnosis of 10 months and 20 months, re-
spectively. Delayed diagnosis was associated with advanced
tumor stage and early death. These patients were primarily
diagnosed with probable FNH at initial presentation at an
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outside institution. One of these 2 patients presented ini-
tially in the early days of clinical introduction of gadoxetic
acid. 3 patients had history of TACE with the last interven-
tion 3, 8, and 12 months, respectively, prior to gadoxetic
acid-enhanced MRI.
Imaging
Gadoxetic acid-enhanced MRI was performed between
September 2007 and May 2016. All scanners were 1.5 T
devices (Siemens Magnetom Avanto or Siemens Magnetom
Aera, Siemens Healthineers, Erlangen, Germany). Specific
sequence parameters such as relaxation times and echo
times differed between individual MRI protocols. General
sequence design is summarized as follows: T2wi was half-
Fourier acquisition single-shot turbo spin echo imaging in
5 of 6 examinations and turbo spin echo imaging in 1
examination. Slice thicknesses were 6 mm. T1wi without
fat saturation was two-dimensional fast low angle shot
Fig. 1 Image panel of patients #1, #2, and #3 displaying representative sections through individual fibrolamellar carcinoma in non-contrast
enhanced techniques including T2 weighted imaging (T2wi), T1 weighted imaging (T1wi), and diffusion weighted imaging using high
b-values (DWI)
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imaging in all 6 examinations. Slice thicknesses were 6 mm.
DWI was echo planar imaging in all 6 examinations. The
highest available b-values were 800 s/mm2 in 5 examina-
tions, 600 s/mm2 in 1 examination. Slice thicknesses were
6 mm. Pre- and post-contrast T1-weighted imaging with
fat-saturation was three-dimensional fast low angle shot
imaging in all 6 examinations. Slice thicknesses were 3 mm.
HBP was acquired with a median delay after HAP of
18:06 min (range, 16:44–20:43 min). Details on contrast
material injection were available for 3 patients. In 2 of
these, contrast material was injected with a rate of 1 ml/s
and in 1 with a rate of 2 ml/s. Contrast material injection
was followed by a saline flush. The contrast material vol-
ume was weight dependent and was 10 ml at a maximum
with 0.025 mmol/ml gadoxetic acid.
Lesion features
In 5 of 6 patients the FLC was unifocal. In 1 patient FLC
was multifocal with disseminated confluent lesions within
the whole liver. In this patient, only the predominant part
Fig. 2 Image panel of patients #4, #5, and #6 displaying representative sections through individual fibrolamellar carcinoma in non-contrast
enhanced imaging techniques including T2 weighted imaging (T2wi), T1 weighted imaging (T1wi), and diffusion weighted imaging using high
b-values (DWI)
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of the lesion was evaluated. Thus, the evaluated FLCs had
a median maximum diameter of 10.5 cm (range, 8.8–
14.0). Panels of representative images of each FLC are
shown in Figs. 1, 2, 3, and 4. Imaging features are summa-
rized in Table 2.
In HBP, all FLCs were hypointense compared with back-
ground liver parenchyma. The CEI indicated presence of
hepatobiliary contrast enhancement in all FLCs (Fig. 5).
The mean CEI averaged over all FLCs was 1.35 indicating a
FLC SI increase of 35% in HBP compared with pre-contrast
T1wi normalized to muscle SI. Mean SI of FLCs and lum-
bar muscle and the CEI are shown in Table 3. In HAP, 5
FLCs had predominantly arterial hyperenhancement and 1
FLC had arterial hypoenhancement in lesion components
considered viable. In PVP, 4 FLC were predominantly
hypointense and 2 FLC was predominantly isointense in
lesion components considered viable. The enhancement
pattern was considered APHE/WO pattern in 3 FLCs.
Fig. 3 Image panel of patients #1, #2, and #3 displaying representative sections through individual fibrolamellar carcinoma in contrast enhanced
imaging techniques including hepatic arterial phase T1 weighted imaging (HAP), portal venous phase T1 weighted imaging (PVP), and
hepatobiliary phase T1 weighted imaging (HBP). In patients with history of TACE prior to gadoxetic acid enhanced MRI (#2, #3) areas of non-
viable tumor are indicated in the portal venous phase (arrows) and areas of viable tumor are indicated in the hepatic arterial phase (star)
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T1wi and T2wi were available in all patients. In T1wi, 5
FLCs were predominantly hypointense, and 1 FLC was pre-
dominantly isointense compared to background liver par-
enchyma. In T2wi, 5 FLCs were predominantly but
heterogeneously hyperintense and 1 FLC was predomin-
antly isointense compared to background liver parenchyma.
DWI and apparent diffusion coefficient (ADC) maps
were available in all patients. In DWI with high b-value,
5 FLCs were predominantly hyperintense and 1 FLC was
predominantly isointense compared to background liver
parenchyma. In ADC map, 4 FLCs were predominantly
hyperintense and 2 FLCs were predominantly isointense
compared to background liver parenchyma.
Intrahepatic bile duct dilatation, bile duct tumor throm-
bosis, and portal vein thrombosis were present in 3, 1, and
1 patient, respectively. Intralesional necrosis and intrale-
sional hemorrhage were present in 2 and 0 patients, re-
spectively, of those patients without history of TACE.
Fig. 4 Image panel of patients #1, #2, and #3 displaying representative sections through individual fibrolamellar carcinoma in contrast enhanced
imaging techniques including hepatic arterial phase T1 weighted imaging (HAP), portal venous phase T1 weighted imaging (PVP), and
hepatobiliary phase T1 weighted imaging (HBP). In patients with history of TACE prior to gadoxetic acid enhanced MRI (#5) areas of non-viable
tumor are indicated in the portal venous phase (arrows) and areas of viable tumor are indicated in the hepatic arterial phase (star)
Palm et al. Cancer Imaging  (2018) 18:9 Page 7 of 10
Discussion
In the present analysis on gadoxetic acid-enhanced MRI of
6 patients with histology-proven FLC, contrast enhancement
during HBP was present in all FLCs according to calculation
of the corrected FLC enhancement index. At visual as-
sessment, all FLCs were hypointense compared with
background liver parenchyma. Important imaging features
identified frequently in other sequence techniques include
heterogeneous hyperintensity in T2wi, hyperintensity in
DWI using high b-values, arterial phase hyperenhance-
ment followed by venous wash-out after injection of con-
trast material, and presence of accompanying findings
generally associated with malignancy.
FLC is an infrequent form of HCC mainly occurring
equally in female and male patients of younger age with-
out underlying liver disease. Only 20% of FLCs are found
in cirrhotic livers [1]. Rarity of FLC and communalities
of FLC with other liver lesions may be reasons for pref-
erence of benign differential diagnoses in conventional
imaging studies and for delayed time to FLC diagnosis.
In two of our patients, FLCs were mistaken for FNH at
initial presentation. Prolonged time to FLC diagnoses
was associated with poor outcome in these cases.
Among benign liver lesions that may be erroneously pre-
ferred over malignancy in patients without chronic liver
disease, FNH is the most important misdiagnosis in cases
of FLC. Mistaking FLC for FNH may have disastrous con-
sequences on patient prognosis if tumor progression during
the interval to FLC diagnosis leads to worsening of tumor
stage and/or impossibility of curative resection. In patients
diagnosed with FLC, positive lymph node status, distant
metastatic disease and incomplete resection are associated
with decreased survival [10, 11].
Both FLC and FNH are predominantly characterized
by generally subtle deviations of signal intensities in pre-
contrast T1wi and T2wi compared to background liver
parenchyma, arterial hyperenhancement, and presence
of a central scar. Imaging features that may favor FLC
over FNH in MRI are greater heterogeneity of lesion tex-
ture of FLC including necrosis and hemorrhage, hypoin-
tensity of the central scar of FLC in T2wi, and portal
venous hypoenhancement [12]. Calcifications are re-
ported to be present in approximately 50% of FLCs and
not in FNH but are depicted insufficiently in MRI [13].
These imaging features are, however, unreliable discrimi-
nators: E.g., the signal intensity of the central scar in
a b
Fig. 5 Assessment of the corrected enhancement index (CEI) in patient #4. a shows the pre-contrast scan. b shows the hepatobiliary phase. CEI is
1.51 indicating a signal increase of 51% normalized to lumbar muscle signal intensity. FLC, fibrolamellar carcinoma; HBP, hepatobiliary phase; SI,
signal intensity
Table 2 Predominant imaging features of fibrolamellar carcinomas
#1 #2 #3 #4 #5 #6
T2wi hyperintense hyperintense isointense hyperintense hyperintense hyperintense
T1wi hypointense hypointense hypointense hypointense hypointense isointense
DWI hyperintense hyperintense isointense hyperintense hyperintense hyperintense
HAP hypoenhanced hyperenhanced hyperenhanced hyperenhanced hyperenhanced hyperenhanced
PVP hypoenhanced isoenhanced hypoenhanced isoenhanced hypoenhanced hypoenhanced
HBP hypoenhanced hypoenhanced hypoenhanced hypoenhanced hypoenhanced hypoenhanced
T2wi T2 weighted imaging, T1wi T1 pre contrast weighted imaging, DWI diffusion weighted imaging with high b-value, HAP hepatic arterial phase post contrast T1
weighted imaging, PVP portal venous phase post contrast T1 weighted imaging, HBP hepatobiliary phase post contrast T1 weighted imaging
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T2wi has been shown to be variable [14]. We did not
specifically analyze the presence of a central scar and its
imaging features in this study, because TACE, which has
been performed in 3 of our patients, was considered to
affect central scar characterization within treated lesion
components.
Gadoxetic acid is a liver-specific gadolinium-based con-
trast agent that was demonstrated to be of great value for
HCC detection in the cirrhotic liver and FNH diagnosis in
ambiguous liver lesions [15, 16]. FNHs are characterized by
strong uptake of gadoxetic acid leading to iso- or hyperin-
tensity in HBP. Conventional HCCs in the cirrhotic liver
are typically hypointense in HBP compared to background
liver parenchyma. However, approximately 10% of HCCs in
the cirrhotic liver are reported to be not hypointense in
HBP due to retained expression of the OATP8 receptor in-
ternalizing gadoxetic acid into the hepatocyte [17]. In the
non-cirrhotic liver, 5 of 27 HCCs were not hypointense in
HBP in a study by Kim et al. [18], but it was not reported if
FLCs were included. Thus, precise data on signal behavior
of FLC in gadoxetic acid-enhanced MRI are scarce.
In one case report of a pediatric FLC patient the tumor
was considered to not show uptake of gadoxetic acid in
HBP [19]. In a larger cohort of 37 FLCs only one gadoxetic
acid-enhanced MRI was performed, and the tumor was
uniformly hypointense in HBP compared with background
liver parenchyma [14]. Apart from that, there are appar-
ently only exemplary case presentations available in review
articles on liver imaging showing hypointensity of FLC in
HBP as well [20–22]. Interestingly, in one illustrative FLC
case, uptake of gadoxetic acid in HBP with focal intrale-
sional areas of isointensity was shown by Ringe et al. [22].
To our knowledge, quantitative data on uptake of gadoxetic
acid of FLCs or conventional HCC in HBP have not been
reported so far. Our case series shows that contrast material
uptake may be generally measurable even in FLCs that are
in total hypointense compared with background liver par-
enchyma. This suggests that OATP8 expression is reduced
but probably generally present in FLCs.
Concerning DWI in FLC, published experience was
very limited so far, but diffusion restriction was sug-
gested to be the most salient finding [12]. The FLCs
assessed in our study were qualitatively predominantly
isointense (n = 1) or predominantly hyperintense (n = 4)
in the ADC map compared to background liver paren-
chyma. As other groups have shown that the majority of
FNHs are mildly hyperintense in DWI when using high
b-values and that the ADC values of FNHs have sub-
stantial overlap with the ADC value of background liver
parenchyma, we suppose that DWI may not be helpful
for distinguishing FLC from FNH either [23, 24].
Limitations
This single-center study is limited by the small case
number due to rarity of the tumor. However, to the best
of our knowledge, so far no larger series on gadoxetic
acid enhanced MRI of FLC has been reported. Moreover,
in 3 of 6 patients TACE had been performed prior to ac-
quisition of gadoxetic acid-enhanced MRI. To ensure a
reasonably large study cohort, these patients were not
excluded from analysis, but only FLC components were
analyzed that progressed after TACE to address possible
effects of TACE on lesion features. There was technical
heterogeneity of MRI protocols, especially concerning
DWI. Thus, ADC value calculation was not feasible. We
did not carry out a comparative analysis between FLC
and FNH. However, imaging features of FNH including
DWI and HBP are well known and analysis of these was
suggested not to enhance the data significantly.
Conclusion
A variable extent of hepatobiliary gadoxetic acid uptake is
suggested to be generally present in FLCs. However, the
observation of hypointensity of active FLC components in
HBP of gadoxetic acid-enhanced liver MRI compared with
background liver parenchyma underscores the role of
gadoxetic acid for non-invasive diagnosis of FLC and its
importance in the diagnostic work-up of indeterminate
liver lesions including FNH.
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